Mantle cell lymphoma: standards and therapeutic news

被引：1
|
作者：
Le Calloch, Ronan [1 ]
Voldoire, Maud [2 ]
Le Gouill, Steven [2 ]
机构：
[1] CHRU Brest, Inst Canc Hematol, Serv Hematol Clin, Brest, France
[2] CHU Nantes, Serv Hematol Clin, UMR892, Nantes, France
来源：
HEMATOLOGIE | 2015年 / 21卷 / 03期
关键词：
mantle cell lymphoma;
D O I：
10.1684/hma.2015.1021
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Mantle cell lymphoma (MCL) is a rare and agressive form of non Hodgkin's lymphoma with one of the worst outcomes. The last decades have established a standard treatment based on the use of cytarabine combined with rituximab followed by a therapeutic intensification and autologous transplantation in young patients. Despite this, LCM remains an aggressive entity with many relapses. Currently, a new era is emerging with the development of new targeted therapies that are coming to change our attitudes and therefore the prognosis of this disease. This review presents the current standard treatment and therapeutic developments in MCL.
引用
收藏
页码：169 / 176
页数：8
相关论文
共 50 条
  • [41] Mantle cell lymphoma: Diagnostic criteria, clinical aspects and therapeutic problems
    Meusers, P
    Hense, J
    Brittinger, G
    LEUKEMIA, 1997, 11 : S60 - S64
  • [42] Unlocking New Therapeutic Targets and Resistance Mechanisms in Mantle Cell Lymphoma
    Colomer, Dolors
    Campo, Elias
    CANCER CELL, 2014, 25 (01) : 7 - 9
  • [43] FoxM1: A New Therapeutic Target for Mantle Cell Lymphoma
    Guo, Hui
    Zhang, Hui
    Ahmed, Makhdum
    Liu, Yang
    Huang, Shengjian
    Zhang, Victoria
    Wang, Jeffrey
    Lopez, Elyse
    Lorence, Elizabeth A.
    Wang, Jacqueline
    Balaji, Swathi
    Maria, Merolle
    Jiang, Changying
    Nomie, Krystle
    Wang, Michael
    Zhang, Liang
    BLOOD, 2017, 130
  • [44] Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma
    Lakhotia, Rahul
    Melani, Christopher
    Dunleavy, Kieron
    Pittaluga, Stefania
    Saba, Nakhle
    Lindenberg, Liza
    Mena, Esther
    Bergvall, Ethan
    Lucas, Andrea Nicole
    Jacob, Allison
    Yusko, Erik
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Wiestner, Adrian
    Wilson, Wyndham H.
    Roschewski, Mark
    BLOOD ADVANCES, 2022, 6 (08) : 2667 - 2680
  • [45] Mantle Cell Lymphoma: Taking Therapeutic Advantage of New Insights into the Biology
    Tang, Tiffany
    Martin, Peter
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (03) : 254 - 261
  • [46] Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma
    Adalgisa Condoluci
    Davide Rossi
    Emanuele Zucca
    Franco Cavalli
    Current Oncology Reports, 2018, 20
  • [47] Mantle Cell Lymphoma: Taking Therapeutic Advantage of New Insights into the Biology
    Tiffany Tang
    Peter Martin
    Current Hematologic Malignancy Reports, 2014, 9 : 254 - 261
  • [48] ICL670 AS A THERAPEUTIC AGENT AGAINST MANTLE CELL LYMPHOMA
    Granot, G.
    Vazana-Barad, L.
    Mor-Tzuntz, R.
    Granot, G.
    Dreyling, M.
    Nathan, I.
    Shpilberg, O.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 182 - 183
  • [49] MANTLE CELL LYMPHOMA
    Dreyling, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 32 - 32
  • [50] MANTLE CELL LYMPHOMA
    Halahleh, Khalid
    LEUKEMIA RESEARCH, 2015, 39 : SS8 - SS9
12345